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Review Article
Clinical Decision Making: Managing Postprandial 
Hyperglycemia
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Abstract
The primary objective of treating all patients with diabetes is to establish and maintain near-normal blood 
glucose levels to prevent microvascular and macrovascular complications. The glycated hemoglobin 
(HbA1c) is the accepted standard for monitoring overall glycemic control with treatments and management 
strategies traditionally targeting fasting and preprandial glucose levels. However, postprandial glucose 
levels also contribute to HbA1c, and optimization of glycemic control may also require targeting these 
values. Exaggerated postmeal glucose excursions are common in patients with diabetes, and postprandial 
hyperglycemia (PPHG) is an independent risk factor for cardiovascular disease. Regular self-monitoring 
of blood glucose concentrations (SMBG) at appropriate times can detect PPHG, provide patient feedback 
regarding meals and lifestyle, and monitor response to therapy. SMBG can also help detect fluctuations in 
blood glucose levels, which may be an additional risk factor for complications, independent of HbA1c. New 
therapeutic options that specifically target postprandial glucose levels may improve overall glycemic control 
and reduce the risk of microvascular and macrovascular complications. ©
INTRODUCTION
Establishing and maintaining tight glycemic control is important for minimizing the microvascular and 
macrovascular complications of diabetes.1,2 There is 
a close correlation between the risk of complications 
and the glycosylated hemoglobin (HbA1c) value. HbA1c
provides a measure of overall mean glycemic exposure 
resulting from fasting, preprandial, and postprandial 
glucose concentrations and is the gold standard for 
monitoring control. 
Although preprandial and fasting plasma glucose 
(FPG) concentrations have been considered the primary 
measures of daily glucose control, postprandial 
glucose (PPG) levels are equally, more important.3
Postprandial hyperglycemia (PPHG) has been linked 
to cardiovascular morbidity and mortality even when 
HbA1c values are in the nondiabetic range,
4-6 whereas 
elevated FPG concentrations are not independently 
associated with increased cardiovascular disease (CVD) 
risk.7,8 Additionally, acute glucose fluctuations appear 
to exhibit a more specific triggering effect on oxidative 
stress than does chronic sustained hyperglycemia.9
Such fluctuations can be detected by self-monitoring of 
*University College London Hospital, Department of Endocrinology 
and Diabetes, London, United Kingdom. **Chairman and Chief of 
Diabetology, Dr Mohan’s Diabetes Specialities Centre & Madras 
Diabetes Research Foundation, Chennai, India.
blood glucose (SMBG) but not by HbA1c. Since therapies 
specifically targeting PPHG can reduce postprandial 
glucose levels, HbA1c values, and CVD risk,
10,11 strategies 
to reduce PPHG and excessive glycemic excursions may 
be particularly important in minimizing the risk of long-
term complications. One important component of these 
strategies is SMBG, which, when used together with 
appropriate patient education, is effective for detecting 
and managing PPHG. SMBG can inform patients 
and their healthcare professionals about the effects 
of food choices, medications, exercise, and stress on 
glucose levels throughout the day, thus complementing 
information provided by HbA1c values.
12 In addition, 
several new therapeutic options specifically targeting 
PPHG have expanded the ability to optimize glycemic 
control by tailoring therapy to the individual patient. 
This article will discuss the importance of detecting and 
managing PPHG and glycemic excursions, examine the 
role of SMBG, and review new and emerging treatment 
options.
Clinical Significance of PPHG
PPHG has been identified as an independent risk 
factor for CVD in patients with or without diagnosed 
diabetes, suggesting that PPHG may be a better 
predictor of risk than is FPG or HbA1c alone (Table 
1).4-6,10,13 PPHG, but not FPG, is a significant predictor 
of subsequent myocardial infarction (MI) and death 
in patients with newly diagnosed type 2 diabetes.5 In 
addition, reductions in carotid intima-media thickness 
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(CIMT) have been linked to changes in postprandial 
but not fasting hyperglycemia or HbA1c,
10 and PPHG 
has been associated with the development of diabetic 
nephropathy and retinopathy.14,15 
Many complex biochemical and molecular events 
have been implicated in hyperglycemia-induced 
tissue damage.8,16,17 At least 4 biochemical pathways 
are thought to be involved in vascular damage, and 
hyperglycemia-induced mitochondrial superoxide 
production is thought to be the unifying mechanism 
for all 4 pathways (Table 2).16 A recent study suggests 
that acute glucose fluctuations lead to increased urinary 
excretion of 8-iso-prostaglandin F2α, a marker of 
oxidative stress.9
Treatment of PPHG Improves Glycemic Control 
and Reduces Diabetic Complications
Therapies focusing on PPHG have successfully 
reduced PPG levels,18 enhanced glycemic control 
(HbA1c),
19,20 and may improve clinical outcomes as 
suggested by studies showing regression of CIMT10 and 
a reduced risk of cardiovascular events.11 For example, 
targeting of PPHG with a sulfonylurea plus insulin 
lispro resulted in better glycemic control than did a 
sulfonylurea alone or therapies targeting fasting or 
preprandial glucose.19,20 Patients with type 2 diabetes 
treated with the insulin secretagogue repaglinide, which 
increases insulin secretion following meals, had a greater 
decrease in peak and area-under-the-curve glucose 
levels than did those who received the sulfonylurea 
glyburide (Fig. 1). Regression of CIMT occurred in 52% 
of subjects receiving repaglinide versus 18% of those 
receiving glyburide (P=.01), suggesting an association 
between regression of CIMT and reductions in PPHG, 
but not FPG.10
In patients with impaired glucose tolerance, 
treatment with the α-glucosidase inhibitor acarbose, 
which delays or prevents absorption of carbohydrates 
by the gut, resulted in a 49% relative risk reduction in 
overall cardiovascular events compared with placebo 
(2.5% absolute risk reduction, P=.03).11 This reduction 
was primarily due to a reduced risk of MI (91% relative 
risk reduction, P=.02). Although this study did not 
actually measure PPG levels, other studies have shown 
that acarbose has an effect on these values.18
Table 1 : Morbidity and mortality related to postchallenge and postprandial hyperglycemia
Study Patients  Key Findings
DECODE study13 10 prospective studies among 15,388 men and 2-hour blood glucose levels following 75-g 
7126 women not previously diagnosed with diabetes  OGTT better predictor of all-cause and 
cardiovascular deaths than FBG levels
Chicago Heart 12,220 men with diabetes or Increased risk of CVD mortality with 
Association6 asymptomatic hyperglycemia higher postload glucose level (after 50-g OGTT)
Temelkova- 582 men and women at  2-hour blood glucose levels and spikes more  
Kurktschiev et al4 risk for type 2 diabetes strongly associated with CIMT than FPG 
or HbA1c 
Diabetes Intervention 1139 men and women with newly PPHG, but not FPG, significant risk 
Study5 diagnosed type 2 diabetes factor for MI and mortality
Campanian Postprandial 93 men and 82 women with type 2 diabetes Reduction of PPHG, but not FPG, 
Hyperglycemia Study10 not previously drug-treated associated with reductions in CIMT
DECODE, Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe; OGTT, oral glucose tolerance test; FBG, fasting 
blood glucose; CVD, cardiovascular disease; CIMT, carotid intima-medial thickness; HbA1c glycosylated hemoglobin; MI, myocardial 
infarction.
Fig. 1 : Effect of therapy specifically targeting postprandial glucose. 
Glucose peaks (top) and curves (bottom) after main meal of the day, 
before and after study completion in patients treated with repaglinide or 
glyburide. Adapted with permission from Esposito K et al. Circulation. 
2004;110:214-219.10
Table 2 : Postprandial hyperglycemia and tissue damage: 
proposed pathophysiologic mechanisms16
 Hyperglycemia-induced mitochondrial superoxide 
 production leads to:
 – Increased flux in polyol pathway 
 – Increased intracellular formation of advanced glycation 
  end-products 
 – Protein kinase C activation
 – Increased flux through hexosamine pathway
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SMBG HELPS IDENTIFY PATIENTS AT 
GREATEST RISK FOR POSTPRANDIAL 
GLYCEMIC EXCURSIONS
It is important to identify patients at risk of PPHG or 
excessive glycemic excursions and to regularly monitor 
their PPG levels. Excessive postprandial glycemic 
excursions are common in patients with type 2 diabetes, 
even those considered well controlled according to 
HbA1c values and FPG levels (Fig. 2).
21-24 PPHG is one of 
the earliest defects in diabetes and is the predominant 
contributor to HbA1c at values below 8.4% (Fig. 3).
25
HbA1c is an integrated measure of glycemic exposure 
over the previous 2 to 3 months. Although PPHG 
may contribute more at lower HbA1c values, it is still 
not possible to use HbA1c to identify patients with 
postprandial glycemic excursions or isolated PPHG, 
whereas appropriately timed SMBG is ideal for detecting 
and monitoring PPHG. Glucose profiles, in which 
patients monitor at different times throughout the day 
or over several days to determine representative diurnal 
glucose levels, can help detect PPHG. Paired-meal SMBG 
testing, or testing before and 1 to 2 hours after meals, 
can evaluate the amplitude of glycemic excursions and 
can educate patients and their healthcare professionals 
about dietary habits. Unlike FPG, meal-based SMBG 
may enable patients to see the effects of their meal 
choices and portion sizes.26 Postprandial SMBG values 
are often the highest glucose readings of the day and 
may motivate patients to avoid problem foods, increase 
physical activity to manage hyperglycemic excursions, 
or evaluate and adjust insulin doses.26,27 
In addition to detecting postprandial excursions, 
SMBG may facilitate significant improvement in 
glycemic control.12,28-30 The quality of research performed 
on the efficacy of SMBG has been comprehensively 
reviewed elsewhere and concerns about the quality of 
the studies expressed31; nevertheless, some evidence 
does exist for efficacy. Schwedes et al investigated the 
effect on HbA1c of meal-related SMBG compared to no 
SMBG in non–insulin-treated patients.28 In the 6-month 
study, patients in the intervention group performed 
SMBG before and 1 hour after main meals on 2 days 
of the week, kept a blood glucose/eating diary, and 
received standardized counseling designed to promote 
self-reflection on the results of SMBG testing. Patients in 
the control group received nonstandardized counseling 
on diet and lifestyle. The intervention group achieved 
a significant reduction in HbA1c values compared with 
controls (1.0% vs 0.54%, P=.0086) (Fig. 4). The authors 
noted that patients in the SMBG group performed twice 
as many SMBG measurements as requested because 
patients were experimenting with their favorite meals.28
Similarly, a study by Muchmore et al showed that meal-
Fig. 2 : Glucose profile illustrating postprandial glucose (PPG) 
excursions. Representative 24-hour glucose profile generated by 
continuous glucose monitoring showing nocturnal hypoglycemia and 
significant daily PPG increases. Reprinted with permission from Hay LC 
et al. Diabetes Technol Ther. 2003;5:19-26.24
Fig. 3 : Influence of fasting and postprandial glucose by glycosylated 
hemoglobin (HbA1c). Relative contributions of postprandial (open bars) 
and fasting (filled bars) hyperglycemia to overall hyperglycemia by HbA1c 
quintiles. Asterisk denotes a significant difference between fasting and 
postprandial glucose levels according to paired t-test.
((Permission requested from Diabetes Care))
Adapted with permission from Schwedes U et al. Diabetes Care. 
2002;25:1928-3228
Fig. 4 : Effect of self-monitoring of blood glucose (SMBG) on changes 
in glycosylated hemoglobin (HbA1c) over time. There was a statistically 
significant between-group difference at 24 weeks favoring SMBG (filled 
circles) versus controls (open circles) (P=.0086).
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based SMBG (before and 2 hours after meals for the first 
month) combined with dietary carbohydrate counting 
led to a significant decrease in HbA1c values (1.54%, 
P<.05) from baseline over the 44-week study.29 This 
study of 23 overweight patients with type 2 diabetes 
compared SMBG and carbohydrate counting (n=12) to 
a behavioral weight control program with no SMBG 
(n=11). Patients in the control group did not achieve 
a significant decrease in HbA1c values (0.84%, P>.3) 
from baseline; while patients in the intervention group 
improved by 1.54% the same interval (p < 0.5). The 
differences between the 2 groups was not significant 
at the study end. This study demonstrated the value of 
linking SMBG measurements directly to carbohydrate 
consumption.
OPTIONS FOR MANAGING PPHG
The Role of Diet and Exercise
Dietary counseling, regular physical exercise, and 
weight loss have been recommended for all patients 
with diabetes.32-34 SMBG may help patients understand 
how food choices and exercise affect their blood glucose 
levels.35 The total amount and nature (composition, 
portion size, preparation method, consumption, and 
digestion rate) of the carbohydrates consumed are 
all important determinants of PPG levels, and low 
carbohydrate/low glycemic index diets can reduce 
PPHG, at least in the short-term.35-38 SMBG testing 
around meals or following exercise may be the best way 
to determine how certain foods or habits affect blood 
glucose levels.26 
Newer Pharmacotherapeutic Strategies to Lower 
FBG and PPG 
Many oral agents successfully lower both FPG and 
PPG levels but may lose their effectiveness over time.39
Thus, combinations of agents with complementary 
mechanisms of action may provide better control of 
FPG and PPG levels.40 These combinations include 
agents that specifically target PPHG (Table 3), including 
α-glucosidase inhibitors, short-acting insulinotropic 
agents, amylin analogues, glucagon-like peptide-1 
(GLP-1) analogues, dipeptidyl peptidase-IV (DPP-IV) 
inhibitors, and rapid-acting insulin analogues. 
α-Glucosidase inhibitors such as acarbose and 
miglitol inhibit intestinal tract α-glucosidases and 
pancreatic α-amylase.39 Although monotherapy with 
these agents reduces overall HbA1c values less than 
do sulfonylureas or metformin, the former are useful 
when PPHG is the primary problem.39 Short-acting 
insulinotropic agents, including repaglinide and 
nateglinide, dissociate faster from their receptors 
than do the sulfonylureas, mitigating the potential 
for delayed hypoglycemia although having a similar 
overall incidence of hypoglycemia.39 Rapid-acting 
insulin analogues such as insulin lispro are absorbed 
quickly but have a shorter duration of action than that 
of regular human insulin.39 When taken just prior to 
meals, they target PPHG. Pramlintide, an analogue of 
the glucoregulatory peptide amylin, which is deficient 
or suppressed in patients with diabetes, lowers 
postprandial glucose excursions and HbA1c values.
41 The 
GLP-1 analogue exenatide, which has a longer duration 
of action than that of naturally occurring GLP-1, reduces 
FPG and PPG values, decreases appetite, and delays 
gastric emptying.42 The DPP-IV inhibitor sitagliptin 
and vildagliptin delay the degradation of endogenous 
GLP-1, lower HbA1c values, and help improve glycemic 
control.43,44
SUMMARY
Traditionally, diabetes management has focused on 
HbA1c for long-term glycemic control and FPG for day-
Table 3 : Classification and mode of action of antidiabetic agents with potential use in combination therapy 39,40,42-44
Mode of Action Class  Examples Primary Target
Augment insulin concentration Sulfonylureas Glyburide FPG
Benzoic acid derivatives Repaglinide PPG
Amino acid derivatives Nateglinide PPG
Increase insulin sensitivity Biguanides Metformin FPG
Thiazolidinediones Rosiglitazone FPG
Reduce intestinal breakdown α-Glucosidase inhibitors Acarbose PPG 
of complex carbohydrates 
Decrease gastric emptying rates;  Amylin analogues Pramlintide PPG 
reduce postprandial glucagon secretion; 
promote hepatic glycogen storage  
Enhance glucose-dependent insulin  GLP-1 analogues Exenatide PPG 
secretion; increase glucose disposal, DPP-IV inhibitors Vildagliptin PPG 
lipogenesis, and glycogen synthesis; Sitagliptin PPG 
decrease gastric motility and delay 
gastric emptying  
Insulin-like actions Rapid-acting insulin Insulin lispro PPG 
analogues 
FPG, fasting plasma glucose; PPG, postprandial glucose; GLP-1, glucagon-like peptide-1; DPP-IV, dipeptidyl peptidase-IV.
Adapted with permission from Van Gaal LF, De Leeuw IH. Diabetologia. 2003;46(suppl 1):M44-M50.40
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to-day monitoring. PPHG is now increasingly recognized 
as an important risk factor for CVD in patients with 
diabetes or prediabetes. PPG concentrations may be 
elevated in patients who are seemingly well controlled 
with diet, exercise, and medical therapy, even those 
with normal FPG and HbA1c values. SMBG may 
complement information provided by HbA1c as it 
provides information on glucose excursions in response 
to daily events, meals, medications, exercise, and illness. 
To realize the full potential of SMBG, patients must be 
educated on how and when to monitor and what steps to 
take in response to high or low blood sugar levels. New 
and emerging medications specifically target PPHG in 
patients experiencing postprandial glycemic excursions. 
The combination of improved detection and monitoring 
of PPHG and effective medications to address it may 
help establish optimal glycemic control and reduce 
the microvascular and macrovascular complications of 
diabetes. There is a need for high-quality studies looking 
at the impact of reduction in PPHG on the incidence of 
CVD. 
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